ArticleJournal of virology2003
In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00908544 (NEW ERA STUDY - HIV and Eradication), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0
Who cites it
27 citing papers in PubMed.
- ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.PLoS pathogens · 2007Trial
- Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.Journal of virology · 2004Trial
- Superinfection promotes replication and diversification of defective HIV-1 proviruses in people with non-suppressible viraemia.Nature microbiology · 2025Article
- Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques.Frontiers in immunology · 2023Article
- Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01.Frontiers in immunology · 2021Article
- CD8+ lymphocyte control of SIV infection during antiretroviral therapy.PLoS pathogens · 2018Article
- Mathematical modeling of within-host Zika virus dynamics.Immunological reviews · 2018Review
- Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.BMC infectious diseases · 2016Article
- Targeting the Brain Reservoirs: Toward an HIV Cure.Frontiers in immunology · 2016Review
- Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.AIDS research and human retroviruses · 2015Article
- Modeling the within-host dynamics of HIV infection.BMC biology · 2013Review
- Contribution of follicular dendritic cells to persistent HIV viremia.Journal of virology · 2013Article
- Cell-associated HIV RNA: a dynamic biomarker of viral persistence.Retrovirology · 2013Review
- A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients.PLoS computational biology · 2011Article
- Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.Retrovirology · 2010Review
- Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Article
- Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.AIDS research and treatment · 2010Article
- Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography.Antimicrobial agents and chemotherapy · 2009Article
- Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.PLoS computational biology · 2009Article
- Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.AIDS (London, England) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Three of five virally suppressed human immunodeficiency virus type I (HIV-1)-infected patients treated with highly active antiretroviral therapy and followed intensively with a supersensitive reverse transcriptase PCR assay with a lower limit of quantitation of 5 copies/ml showed statistically significant viral load decays below 50 copies/ml, with half-lives of 5 to 8 months and a mean of 6 months. This range of half-lives is consistent with the estimated half-life of the latent HIV-1 reservoir in the peripheral blood. Those patients without decay of viral load in plasma may have significant cryptic HIV-1 residual replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.